Key Takeaways:
- Danaher is showing signs of steadier recovery, with first-quarter 2026 revenue up 3.5%, adjusted EPS up to $2.06, and full-year EPS guidance raised.
- DHR is being priced on a mix of improving bioprocessing demand, cautious top-line growth, and investor debate around the Masimo acquisition.
- Danaher stock could reasonably reach around $248 per share by late 2028, based on the valuation model.
- That implies a roughly 27% total return from today’s price of about $195, or around 9% annualized over the next 2.7 years.
What Happened?
Danaher Corporation (DHR) is in focus this week because its latest earnings report gave investors a better read on whether demand is finally improving. Reuters reported that Danaher beat first-quarter profit estimates on strong bioprocessing demand, and the company also raised its full-year adjusted EPS outlook. That was enough to push the stock higher after the release, even though revenue came in slightly below the analyst estimate cited by Reuters.
The tone of the quarter was constructive, but still measured. Danaher said first-quarter 2026 revenue rose 3.5% year over year to $6.0 billion, while non-GAAP core revenue increased 0.5%. CEO Rainer Blair said, “Our team executed well in the first quarter,” and added that strength in Bioprocessing and Life Sciences helped offset weaker respiratory demand at Cepheid.
Investors are also weighing what the recovery means for each business line. Danaher’s supplement showed Biotechnology core growth of 7%, with Bioprocessing up at a high-single-digit rate, while non-respiratory Cepheid growth was positive, but respiratory demand remained a headwind.
The other major piece of the story is the Masimo acquisition. Reuters reported in February that Danaher agreed to buy Masimo for $9.9 billion to expand in patient-monitoring devices, and analysts called the move surprising because it reaches beyond Danaher’s more familiar life sciences and diagnostics lanes.
Here’s why Danaher stock could keep moving from here: investors now need to see steady core growth, solid cash generation, and a clear integration case for Masimo at the same time.
What the Model Says for DHR Stock
We analyzed the upside potential for Danaher stock using valuation assumptions based on a modest growth recovery, durable margins, and a more normalized earnings multiple.
Based on estimates of around 6% annual revenue growth, around 30% operating margins, and a normalized P/E multiple of around 23x, the model projects Danaher stock could rise from $195 to $248 per share.
That would be a 27.4% total return, or a 9.4% annualized return over the next 2.7 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for DHR stock:
1. Revenue Growth: 6%
Danaher’s revenue base is large, but recent growth has been uneven. Sales rose from $23.9 billion in 2024 to $24.6 billion in 2025, and first-quarter 2026 revenue increased another 3.5% year over year to $6.0 billion. So the business is growing again, but the pace is still far below what investors saw during the pandemic-era boom.
The recovery is being driven mainly by Bioprocessing and a better environment in Life Sciences. Danaher said the biotechnology core growth was 7% in the first quarter, and Reuters said stronger demand for bioprocessing tools used in drug manufacturing helped the company beat profit expectations.
Based on analysts’ consensus estimates, we use around 6% annual revenue growth. That matches the model and sits close to Danaher’s own full-year 2026 core revenue outlook of 3% to 6%. It reflects a business with improving demand, but still some drag from respiratory testing and a slower recovery across parts of life sciences.
2. Operating Margins: 30%
Danaher remains a strong margin business even after the recent slowdown. The company posted a 22.0% LTM EBIT margin, and its guided valuation assumption uses an operating margin of around 30%. That higher modeled level fits the company’s long record of operating discipline and the value of its consumables, instruments, and service mix.
Margin quality also shows up in cash flow. Danaher generated about $6.4 billion of operating cash flow and $5.3 billion of free cash flow in 2025, and first-quarter 2026 free cash flow was already about $1.1 billion. Those figures suggest the company can still convert moderate growth into meaningful earnings and cash.
Based on analysts’ consensus estimates, we use around 30% operating margins. That assumes Danaher keeps benefiting from scale, mix, and cost discipline, while avoiding a full return to peak optimism. It also leaves room for some integration costs and the normal ups and downs that come with acquisitions and end-market shifts.
3. Exit P/E Multiple: 29.6x
Danaher’s screen showed an NTM P/E of about 23.2x and an LTM P/E of about 37.7x, while the valuation model uses a normalized exit multiple around 23x. That tells you the model is anchored to forward earnings power, not to the weaker trailing EPS base.
There is a good reason to stay disciplined here. Over the past few years, Danaher’s growth has slowed, and Reuters said some analysts were surprised by the Masimo deal because it stepped outside Danaher’s traditional focus. Even if the acquisition works well over time, investors may wait for cleaner execution before paying a much higher multiple.
Based on analysts’ consensus estimates, we use an exit P/E multiple of around 23x. That sits close to the current forward valuation and still reflects Danaher’s reputation as a high-quality healthcare compounder. But it does not assume the market quickly returns to a richer premium multiple while organic growth is only gradually improving.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for Danaher stock through 2035 show varied outcomes based on life sciences demand, margin execution, and valuation discipline (these are estimates, not guaranteed returns):
- Low Case: Growth stays muted, respiratory headwinds linger, and the multiple compresses faster → 4.6% annual returns
- Mid Case: Danaher keeps recovering across Bioprocessing, Life Sciences, and Diagnostics → 7.2% annual returns
- High Case: Core demand improves more steadily, and margins expand with better mix → 9.7% annual returns
The business still has durable cash generation, strong positions in bioprocessing and diagnostics, and a management team that keeps raising productivity. But the stock will likely move with evidence that growth is broadening, that Masimo can be integrated well, and that life sciences spending keeps normalizing over the next few quarters.
See what analysts think about DHR stock right now (Free with TIKR) >>>
Should You Invest in Danaher Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up DHR, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track DHR alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Danaher stock on TIKR Free→
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
